Literature DB >> 2041011

Dermatomyositis treated with cyclosporin.

G M Kavanagh1, J S Ross, M M Black.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 2041011      PMCID： PMC1293233          DOI： 10.1177/014107689108400519

Source DB:  PubMed          Journal:  J R Soc Med        ISSN： 0141-0768            Impact factor:   18.000


× No keyword cloud information.
  6 in total

1.  Cyclosporine and oncogenesis.

Authors:  I Penn
Journal:  Mt Sinai J Med       Date:  1987-09

2.  Cyclosporin for polymyositis.

Authors:  S van der Meer; J W Imhof; J C Borleffs
Journal:  Ann Rheum Dis       Date:  1986-07       Impact factor: 19.103

3.  Cell-mediated cytotoxicity to muscle in polymyositis. Effect of immunosuppression.

Authors:  R L Dawkins; F L Mastaglia
Journal:  N Engl J Med       Date:  1973-03-01       Impact factor: 91.245

Review 4.  T-lymphocyte inhibition by cyclosporine. Potential mechanisms of action.

Authors:  P M Colombani; A D Hess
Journal:  Biochem Pharmacol       Date:  1987-11-15       Impact factor: 5.858

5.  Cyclosporin in juvenile dermatomyositis.

Authors:  J Heckmatt; N Hasson; C Saunders; N Thompson; A M Peters; G Cambridge; M Rose; S A Hyde; V Dubowitz
Journal:  Lancet       Date:  1989-05-13       Impact factor: 79.321

Review 6.  Current concepts in the idiopathic inflammatory myopathies: polymyositis, dermatomyositis, and related disorders.

Authors:  P H Plotz; M Dalakas; R L Leff; L A Love; F W Miller; M E Cronin
Journal:  Ann Intern Med       Date:  1989-07-15       Impact factor: 25.391
  6 in total
  2 in total

Review 1.  Treatment of inflammatory myopathies.

Authors:  A C Cordeiro; D A Isenberg
Journal:  Postgrad Med J       Date:  2006-07       Impact factor: 2.401

Review 2.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.